Jushi Holdings (JUSH) reported $263M in revenue for fiscal 2025, +2.1% year on year. That ranks #2551 by revenue among 2853 SEC filers and #261 in Healthcare. It posted a net loss of −$68.6M for the same year. Revenue has grown 26.6% a year on average since 2020 ($80.8M then). The fiscal 2025 balance sheet shows $422M in total assets, $24.0M in cash and $199M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $263M | +2.1% | FY20252025-12-31 |
| Gross profitGrossProfit | $114M | −3.7% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $4.9M | −55.3% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$68.6M | −$19.8M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $17.7M | −17.8% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $16.1M | +241.8% | FY20252025-12-31 |
| Total assetsAssets | $422M | −4.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$115M | −$65.1M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $24.0M | +23.2% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $199M | +8.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $66.4M | −$19.8M | Open → |
| Q2 20262026-06-30 | $71.3M | −$7.3M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Jushi Holdings Inc.
- Ticker
- JUSH
- Exchange
- OTC
- SIC classification
- Medicinal Chemicals & Botanical Products (2833)
- Fiscal year end
- 12-31
- CIK
- 0001909747
Filings
- 10-QJul 28, 2026Open filing →
- 10-QMay 12, 2026Open filing →
- 10-KMar 31, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Vireo GrowthVREOF | $269M | −$68.1M |
| Ligand PharmaceuticalsLGND | $268M | $124M |
| Iovance BiotherapeuticsIOVA | $264M | −$391M |
| Jushi HoldingsJUSH | $263M | −$68.6M |
| ArvinasARVN | $263M | −$81.0M |
| Omada HealthOMDA | $260M | −$12.8M |
| SchrodingerSDGR | $256M | −$103M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Jushi Holdings — Key figures |url=https://companiesranked.com/en/company/jushi-holdings |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Jushi Holdings — Key figures. CompaniesRanked. https://companiesranked.com/en/company/jushi-holdingsBibTeX
@misc{companiesranked-en-company-jushi-holdings-2026,
author = {{CompaniesRanked}},
title = {{Jushi Holdings — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/jushi-holdings}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-022436 · March 31, 2026
{{cite web |title=Jushi Holdings — Key figures — 10-K (0001628280-26-022436) |url=https://www.sec.gov/Archives/edgar/data/1909747/000162828026022436/jush-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-31}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.